The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Open accessAbstract
Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. These include a reduced incidence of cardiovascular death and heart failure hospitalization in people with and without diabetes, and those with and without prevalent heart failure. The actual mechanism(s) responsible for these beneficial effects are not completely clear. Several potential theses have been proposed to explain the cardioprotective effects of SGLT2 inhibition, which include diuresis/natriuresis, blood pressure reduction, erythropoiesis, improved cardiac energy metabolism, inflammation reduction, inhibition of the sympathetic nervous system, prevention of adverse cardiac remodeling, prevention of ischemia/reperfusion injury, inhibition of the Na+/H+-exchanger, inhibition of SGLT1, reduction in hyperuricemia, increasing autophagy and lysosomal degradation, decreasing epicardial fat mass, increasing erythropoietin levels, increasing circulating pro-vascular progenitor cells, decreasing oxidative stress, and improving vascular function. The strengths and weaknesses of these proposed mechanisms are reviewed in an effort to try to synthesize and prioritize the mechanisms as they relate to clinical event reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Self-citationThe ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172
Endemann, D. H., & Schiffrin, E. L. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000132474.50966.da · Cited by 1,198
Cited by
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Cardiac Energy Metabolism in Heart Failure
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021) · Circulation Research · doi:10.1161/circresaha.121.318241 · Cited by 1,373
Self-citationAntar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115734 · Cited by 622
Santos-Gallego, C. G., Vargas-Delgado, A. P., Requena-Ibanez, J. A., Garcia-Ropero, A., Mancini, D., Pinney, S., Macaluso, F., Sartori, S., Roque, M., Sabatel-Perez, F., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.008 · Cited by 531
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
Self-citationEmpagliflozin in acute myocardial infarction: the EMMY trial
von Lewinski, D., Kolesnik, E., Tripolt, N. J., Pferschy, P. N., Benedikt, M., Wallner, M., Alber, H., Berger, R., Lichtenauer, M., Saely, C. H., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac494 · Cited by 303
Curtain, J. P., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab560 · Cited by 256
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
Brouwers, S., Sudano, I., Kokubo, Y., & Sulaica, E. M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00221-x · Cited by 257
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.015 · Cited by 114
Xie, Y., Bowe, B., Xian, H., Loux, T., McGill, J. B., & Al-Aly, Z. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00171-7 · Cited by 104
Sfairopoulos, D., Zhang, N., Wang, Y., Chen, Z., Letsas, K. P., Tse, G., Li, G., Lip, G. Y. H., Liu, T., & Korantzopoulos, P. (2022) · EP Europace · doi:10.1093/europace/euab177 · Cited by 76
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62
Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01213-w · Cited by 48
“Moreover, the list of their cardiorenal protective effects is expanding and includes, among others, preventing adverse cardiac remodeling and ischemia/ reperfusion injury, increasing circulating hematopoietic progenitor cells, decreasing epicardial fat mass, decreasing oxidative stress and inflammation, increasing ery…”
BackgroundRazuk, V., Chiarito, M., Cao, D., Nicolas, J., Pivato, C. A., Camaj, A., Power, D., Beerkens, F., Jones, D., Alter, A., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac001 · Cited by 41
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Dagogo-Jack, S., Pratley, R. E., Cherney, D. Z. I., McGuire, D. K., Cosentino, F., Shih, W. J., Liu, J., Frederich, R., Mancuso, J. P., Raji, A., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002484 · Cited by 37
Subramanian, M., Sravani, V., Krishna, S. P., Bijjam, S., Sunehra, C., Yalagudri, S., Saggu, D. K., & Narasimhan, C. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.054 · Cited by 30
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Mortality in Hypertrophic Cardiomyopathy
Aglan, A., Fath, A. R., Eldaly, A. S., Anderson, A. S., Phillips, J. S., Maron, B. J., Maron, M. S., & Rowin, E. J. (2024) · JACC: Advances · doi:10.1016/j.jacadv.2024.100843 · Cited by 29
Current management of hypertrophic cardiomyopathy
Sikand, N., Stendahl, J., Sen, S., Lampert, R., & Day, S. (2025) · BMJ · doi:10.1136/bmj-2023-077274 · Cited by 26
Correale, M., Mazzeo, P., Tricarico, L., Croella, F., Fortunato, M., Magnesa, M., Amatruda, M., Alfieri, S., Ferrara, S., Ceci, V., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01166-2 · Cited by 14
Ansari, P., Khan, J. T., Choudhary, S., Reberio, A. D., Kumar, S., Seidel, V., Abdel-Wahab, Y. H. A., & Flatt, P. R. (2024) · doi:10.20944/preprints202408.1739.v1 · Cited by 89
Metadata
- Authors
- Lopaschuk, G. D., & Verma, S.
- Venue
- JACC: Basic to Translational Science
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 5
- Issue
- 6
- Pages
- 632-644
- ISSN
- 2452-302X (ISSN-L)
- OpenAlex
- W3036816724
- Cited by
- 894
- References
- 107
- FWCI
- 68.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.